Thursday, 18 Oct 2018

You are here

CDC Lyme Disease Surveillance Report

Lyme disease, caused by the spirochete Borrelia burdofgeri, is the most common vector-borne illness reported in the U.S. Cases occur mainly in the Northeast, Mid-Atlantic and upper Midwest as well as certain areas of the Pacific coast, with a geographic distribution based on residence of Ixodes scapularis (Ixodes pacificus on the West Coast), the vectors that transmits Lyme disease.

Lyme disease has been a reportable disease since 1991, with cases reported to the Health Department by both physicians and laboratories. Confirmed or probable cases are then reported to the CDC through the National Notifiable Diseases Surveillance System.

MMWR recently published surveillance data for Lyme Disease in the U.S. from 2008-2015. States with an average annual incidence ≥ 10 confirmed cases per 100,000 population were considered high incidence. During this time period 275,589 cases of Lyme were reported to the CDC and most cases were from regions previously considered to be high incidence.

According to the CDC surveillance report, the top 7 states for Lyme disease in 2015 include

  1. Vermont (78.4 per 100000/yr)
  2. Maine (74.7 per 100000/yr)
  3. Pennsylvania (57.5 per 100000/yr)
  4. Rhode Island (53.4 per 100000/yr)
  5. Connecticut (52.2 per 100000/yr)
  6. New Jersey (43.9 per 100000/yr)
  7. Massachussetts (43 per 100000/yr).

For the most part these counts have remained stable over the years; however, incidence is rising in states that neighbor these regions. Demographics of reported cases are similar to in the past, but in lower incidence areas there were more cases in younger females compared to the past.

We can take away from this that Lyme disease continues to concentrate in known high-incidence areas although the geographic distribution seems to be spreading. This will add to the continuing public health challenge that is Lyme disease, and Lyme should be considered in a patient with a  suggestive clinical presentation even if they are not from a high risk area.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.